四丁酚醇 - CAS号 25301-02-4

物化性质

密度：

1.1
闪点：

113 °C
溶解度：

可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）
LogP：

4.930 (est)
稳定性/保质期：

避免接触强氧化物

计算性质

辛醇/水分配系数(LogP)：

3.94
重原子数：

20
可旋转键数：

3
环数：

2.0
sp3杂化的碳原子比例：

0.59
拓扑面积：

49.8
氢给体数：

1
氢受体数：

3

安全信息

危险品标志：

Xi
安全说明：

S26,S36
危险类别码：

R36/37/38
WGK Germany：

2
海关编码：

29222990

SDS

SDS：d722cb6b31863f76745d2d64f6896454

查看

Name:	Tyloxapol Material Safety Data Sheet
Synonym:
CAS:	25301-02-4

Section 1 - Chemical Product MSDS Name:Tyloxapol Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
25301-02-4	Tyloxapol		unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 25301-02-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Clear light yellow viscous liquid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 0 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.1070g/cm3
Molecular Formula:
Molecular Weight:

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Not available.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 25301-02-4: SM9750000 LD50/LC50:
CAS# 25301-02-4: Oral, mouse: LD50 = >10 gm/kg; Oral, rat: LD50 = >5 gm/kg.
Carcinogenicity:
Tyloxapol - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 25301-02-4: No information available.
Canada
CAS# 25301-02-4 is listed on Canada's DSL List.
CAS# 25301-02-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 25301-02-4 is not listed on the TSCA inventory.
It is for research and development use only.

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Tyloxapol（Triton WR1339）是一种烷基芳基聚醚醇类的非离子液体聚合物，用作液化时的表面活性剂、去除黏脓性的和支气管肺的分泌物。此外，它还能抑制血浆脂解活性，从而分解富含三酰甘油的脂蛋白。

靶点

Target	Value
lipoprotein lipase

体外研究

Tyloxapol 被认为是一种安全的稳定剂。一些研究表明，在上皮细胞和红细胞中，Tyloxapol 可能会产生毒性作用，并在RAW264.7小鼠噬细胞和NIH/3T3细胞中诱导凋亡，甚至导致人Jurkat T淋巴母细胞裂解。然而，这些体外研究结果并不反映 Tyloxapol 的体内作用；它很少在临床中单独应用。

体内研究

在大鼠中，通过静脉注射单次给药400mg/kg的Tyloxapol会导致血浆脂类出现三个不同的阶段变化：相对于基础水平，会先出现急促的线性增加，随后是相对平缓的线性增加，最后则是缓慢减少。此外，Tyloxapol 的处理能增强胰岛素的肺吸收，并在糖尿病大鼠模型中增强吸入型胰岛素的吸收。在糖尿病大鼠模型中，该药物可能显著提升通过气管灌注的胰岛素的降血糖作用，但并未改变LDH活性。

文献信息

OLIGONUCLEOTIDE DECOYS AND METHODS OF USE

申请人：Jones Walter Keith

公开号：US20090099108A1

公开（公告）日：2009-04-16

The present invention describes reagents and methods for using a concatemerized double-stranded oligonucleotide molecules (CODN) for transcription factor decoys. In one embodiment, the concatemers consist of a variable number of end-to-end repeated copies of a short (more than 5, 10, 15, 20, 2, 3035, 40, 45, 50, 75, 100, or more by but generally less than about 3 kb) dsDNA containing a sequence or sequences that act as transcription factor decoys. The present invention also provides for the use of the polymers for CODN/polymer complexes to a specific cell type; thus the agent can be made organ, tissue and/or cell-type specific. In another embodiment, the present invention provides for use of the CODN's in vitro or in vivo, in isolated cells or intact animals in which specific blockade of transcription factors or delivery of DNA or other biological effector is desirable. In one embodiment, this includes use as a research tool, including studies of specific genes and studies to identify specific genes regulated by the transcription factors targeted. In another embodiment, the present invention provides for using polyamides for NF-kB-specific CODN delivery in the treatment of myocardial ischemia/reperfusion and myocardial infarction, heart failure and hypertrophy, cardioprotection, stroke, neuroprotection, sepsis, arthritis, asthma, heritable inflammatory disorders, cancer, heritable immune dysfunctions, inflammatory processes, whether caused by disease or injury or infection, oxidative stress to any organ whether caused by disease, surgery or injury. The decoys may be any transcription factors, including, but not limited to, NF-kB, AP-I, ATF2, ATF3, SP 1 and others.

本发明描述了一种使用串联双链寡核苷酸分子（CODN）作为转录因子诱饵的试剂和方法。在一种实施例中，串联体由一种短的（大于5、10、15、20、25、30、35、40、45、50、75、100或更多，但通常小于约3 kb）双链DNA的端对端重复拷贝构成，其中包含作为转录因子诱饵的一个或多个序列。本发明还提供了将聚合物用于CODN/聚合物复合物对特定细胞类型的使用；因此，该试剂可以被制成特定的器官、组织和/或细胞类型。在另一种实施例中，本发明提供了在离体或体内、在孤立的细胞或完整的动物中使用CODN的方法，其中需要特定的转录因子阻断或DNA或其他生物效应物的递送。在一种实施例中，这包括用作研究工具，包括研究特定基因和研究识别被靶向的转录因子调控的特定基因。在另一种实施例中，本发明提供了使用聚酰胺进行NF-kB特异性CODN递送，用于治疗心肌缺血/再灌注和心肌梗死、心力衰竭和肥厚、心脏保护、中风、神经保护、败血症、关节炎、哮喘、遗传性炎症性疾病、癌症、遗传性免疫功能障碍、炎症过程，无论是由疾病、手术还是损伤或感染引起的，以及对任何器官的氧化应激。诱饵可以是任何转录因子，包括但不限于NF-kB、AP-I、ATF2、ATF3、SP1等。
Polynucleotides and polypeptides associated with the NF-kB pathway

申请人：——

公开号：US20030224486A1

公开（公告）日：2003-12-04

The present invention provides polynucleotides encoding NF-kB-associated polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these NF-kB-associated polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

本发明提供了编码 NF-kB 相关多肽、其片段和同源物的多核苷酸。还提供了载体、宿主细胞、抗体以及生产上述多肽的重组和合成方法。本发明进一步涉及将这些 NF-kB 相关多肽应用于诊断、治疗和/或预防与这些多肽相关的各种疾病和/或失调的诊断和治疗方法。本发明还涉及用于鉴定本发明多核苷酸和多肽的激动剂和拮抗剂的筛选方法。
POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY

申请人：Bristol-Myers Squibb Company

公开号：EP1379540A2

公开（公告）日：2004-01-14
EP1379540A4

申请人：——

公开号：EP1379540A4

公开（公告）日：2005-11-16
POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY

申请人：Bristol-Myers Squibb Company

公开号：EP1628629A2

公开（公告）日：2006-03-01

四丁酚醇 | 25301-02-4

物质功能分类

分子结构分类

物化性质

计算性质

安全信息

SDS

制备方法与用途

文献信息

同类化合物

相关功能分类

相关结构分类

热门分子